The Valley Desk

NCT06926868 · Interventional trial

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Overall registry status Recruiting

Phase 2 · Phase 3

Conditions Breast Neoplasms

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov